Drugs / RD06-03
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06307600 | Mar 2024 → Mar 2025 overdue | B-cell acute lymphoblastic leukemia | Anhui Provincial Hospital | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-06-01 | Imviva Bio | Results Positive Clinical Data of the Universal CAR-T Product RD06-03 in R/R B-ALL presented at ASCO 2025 imvivabio.com ↗
The data presented at ASCO 2025 come from an investigator-initiated Phase I clinical trial conducted at The First Affiliated Hospital of the University of Science and Technology of China. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-06-01 | Imviva Bio | Positive Clinical Data of the Universal CAR-T Product RD06-03 in R/R B-ALL presented at ASCO 2025 imvivabio.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RD06-03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06307600 ↗ |
| Modality | Cell therapy | “RD06-03 CART cell injection” NCT06307600 ↗ |
| Route | Intravenous | “Dosage form: IV injection” NCT06307600 ↗ |